Bafna Pharmaceuticals reported a net profit of ₹1,109.98 lakh for the financial year ended March 31, 2026, marking a substantial increase from ₹415.25 lakh in the previous year. Revenue from operations for FY26 rose to ₹15,061.74 lakh compared to ₹14,585.70 lakh in FY25, driven by growth across its pharmaceutical formulations segment. The company’s earnings per equity share (basic) improved to ₹4.69 from ₹1.76 in the prior year.

Financial Performance

The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, following a recommendation by the Audit Committee. For the quarter ended March 31, 2026, the company recorded a profit of ₹274.91 lakh, up from ₹131.10 lakh in the same period of the previous year. Revenue from operations for the quarter stood at ₹4,223.93 lakh, compared to ₹3,906.00 lakh in Q4FY25.

Operational Highlights and Expenses

Total expenses for FY26 increased to ₹14,440.35 lakh from ₹14,230.11 lakh in the previous year. Key cost components included the cost of material consumed at ₹8,213.53 lakh and employee benefits expenses of ₹2,191.89 lakh. Finance costs rose to ₹366.11 lakh, while depreciation and amortization expenses stood at ₹607.26 lakh. The company noted that exceptional items for the year ended March 31, 2025, included the derecognition of inventory and intangible assets under development.

Regulatory Disclosures and Auditor’s Report

The statutory auditors, M/s. Brahmayya & Co., Chartered Accountants, issued an audit report with an unmodified opinion on the financial results. The auditors drew attention to a GST demand of ₹235.47 lakh and an order for the recovery of GST refunds amounting to ₹331.09 lakh. The company has preferred an appeal against the demand and obtained a stay for the recovery order, stating it does not anticipate any adverse financial outcome based on legal precedents and industry practices.

SRJR Lifesciences LLP, the promoter of bafna pharmaceuticals , has confirmed that no encumbrance was created over the shares held by it in the company during the financial year ended March 31, 2026. This declaration, made directly or indirectly, ensures that the promoter's shareholding remains free from charges such as pledges or hypothecation for the specified period. The confirmation addresses potential concerns regarding the financial leveraging of promoter holdings, which is a key indicator of corporate governance for investors.

The disclosure was formally submitted to the stock exchanges, BSE Limited and National Stock Exchange of India Limited, on April 1, 2026. The communication was addressed to the General Managers of the Listing Departments at both exchanges and the Company Secretary of Bafna Pharmaceuticals Ltd. The filing was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates promoters to disclose any encumbrance on their shareholdings annually.

Regulatory Filing Details

The letter, signed by Upendar Mekala Reddy, Designated Partner of SRJR Lifesciences LLP, provided specific identification details for the security. The confirmation covers the company's shares traded on the exchanges under the symbol BAFNAPH.

The promoter requested the exchanges to take the information on record and acknowledge receipt of the same. A copy of the disclosure was also marked to the Audit Committee of Bafna Pharmaceuticals Ltd.